DelveInsight’s “Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the Traumatic Brain Injury, historical and forecasted epidemiology as well as the Traumatic Brain Injury market trends in the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan.
Discover which therapies are expected to grab the Traumatic Brain Injury Market Share @ Traumatic Brain Injury Market Outlook
Key Takeaways from the Traumatic Brain Injury Market Report
- The increase in Traumatic Brain Injury Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
- As per DelveInsight analysis, the Traumatic Brain Injury market size is projected to expand from a valuation of USD 30 billion in 2024, registering a CAGR of 10.9% through 2034.
- The leading Traumatic Brain Injury Companies such as Oxeia Biopharmaceuticals, Hope Biosciences, Oragenics, SHINKEI Therapeutics, BioVie, Beyond Barriers Therapeutics, AivoCode, Abliva/Owl Therapeutics, Neuroplast, SanBio, and others.
- Promising Traumatic Brain Injury Therapies such as AKUUGO, OXE103, ONP-002, HB-adMSCs, MR-301, and others.
Stay ahead in the Traumatic Brain Injury Therapeutics Market with DelveInsight’s Strategic Report @ Traumatic Brain Injury Market Outlook
Traumatic Brain Injury Epidemiology Segmentation in the 7MM
The epidemiology section of Traumatic Brain Injury offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
- In 2024, the seven major markets (7MM) reported nearly 4.3 million new cases of traumatic brain injury, a figure projected to rise to about 4.5 million by 2034.
- In 2024, the United States recorded approximately 3 million new cases of traumatic brain injury.
- In 2024, the severity-specific distribution of Traumatic Brain Injury in Germany accounted for about 250,000 cases of mild Traumatic Brain Injury, about 10,500 cases of moderate Traumatic Brain Injury, and about 14,000 cases of severe Traumatic Brain Injury.
- Japan recorded approximately 329,000 new cases of traumatic brain injury in 2020, and this incidence is projected to grow at a CAGR of 0.01% over the forecast period.
Download the report to understand which factors are driving Traumatic Brain Injury Epidemiology trends @ Traumatic Brain Injury Prevalence
Traumatic Brain Injury Drugs Market
The Traumatic Brain Injury Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. The total market size of the Traumatic Brain Injury treatment market is anticipated to grow during the forecast period due to the emergence of new and effective treatments, namely ONP-002, HB-AdMSCs, OXE103, and others. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Traumatic Brain Injury are likely to uncover new therapeutic targets and further expand treatment options for patients.
Traumatic Brain Injury Treatment Market Landscape
The Traumatic Brain Injury treatment market landscape has witnessed significant advancements with the approval of AKUUGO in July 2024 as the first cell therapy for improving chronic motor paralysis resulting from Traumatic Brain Injury. Currently, there are no FDA-approved treatments for acute concussion. The current standard of care is rest, followed by a gradual return to normal activity. Off-label therapies, including antidepressants, antiepileptics, antipsychotics, analgesics, antacids, and other symptomatic treatments, are used to manage Traumatic Brain Injury.
To learn more about Traumatic Brain Injury treatment guidelines, visit @ Traumatic Brain Injury Treatment Market Landscape
Traumatic Brain Injury Market Outlook
The report’s outlook on the Traumatic Brain Injury market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Traumatic Brain Injury therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Traumatic Brain Injury drug and late-stage pipeline therapy.
- The total market size of Traumatic Brain Injury in the 7MM was around USD 1,300 million in 2024, estimated to increase substantially by 2034.
- Among the 7MM, the US captured the highest Traumatic Brain Injury market in 2024, covering a total of 85% of the market, followed by Japan.
- In 2024, EU4 and the UK, Germany captured nearly 29% of the total Traumatic Brain Injury market, followed by France (22%) in the 7MM.
Traumatic Brain Injury Drugs Uptake
The drug chapter of the Traumatic Brain Injury report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages and disadvantages of each drug, as well as the latest news and press releases related to Traumatic Brain Injury.
Major Traumatic Brain Injury Companies
Oxeia Biopharmaceuticals, Hope Biosciences, Oragenics, SHINKEI Therapeutics, BioVie, Beyond Barriers Therapeutics, AivoCode, Abliva/Owl Therapeutics, Neuroplast, SanBio, and others.
Learn more about the FDA-approved drugs for Traumatic Brain Injury Treatment @ Drugs for Traumatic Brain Injury Treatment
Scope of the Traumatic Brain Injury Market Report
- Coverage– Global
- Study Period– 2020-2034
- Traumatic Brain Injury Companies– Oxeia Biopharmaceuticals, Hope Biosciences, Oragenics, SHINKEI Therapeutics, BioVie, Beyond Barriers Therapeutics, AivoCode, Abliva/Owl Therapeutics, Neuroplast, SanBio, and others
- Traumatic Brain Injury Therapies– AKUUGO, OXE103, ONP-002, HB-adMSCs, MR-301, and others
- Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury Market Drivers and Barriers
- Traumatic Brain Injury Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Traumatic Brain Injury Drugs in development @ Traumatic Brain Injury Clinical Trials Assessment
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Forecast Methodology
- Traumatic Brain Injury Market Overview at a Glance
- Disease Background and Overview
- Epidemiology and Patient Population of 7MM
- Patient Journey of Traumatic Brain Injury
- Marketed Drugs
- Emerging Drugs
- Traumatic Brain Injury: 7MM Analysis
- Unmet Needs
- SWOT Analysis
- KOL Views
- Market Access and Reimbursement
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
